Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 288.7% in the fourth quarter, Holdings Channel reports. The fund owned 852,893 shares of the company’s stock after acquiring an additional 633,486 shares during the period. Johnson & Johnson accounts for 0.9% of Connor Clark & Lunn Investment Management Ltd.’s investment portfolio, making the stock its 27th biggest holding. Connor Clark & Lunn Investment Management Ltd.’s holdings in Johnson & Johnson were worth $150,664,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Veracity Capital LLC lifted its holdings in Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after buying an additional 59 shares during the period. Sandy Cove Advisors LLC grew its position in Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares in the last quarter. LCM Capital Management Inc grew its position in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares in the last quarter. Arbor Investment Advisors LLC grew its position in Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares in the last quarter. Finally, Sierra Capital LLC grew its position in shares of Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after acquiring an additional 61 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.
Johnson & Johnson Stock Down 1.4 %
Shares of NYSE JNJ opened at $154.41 on Friday. The company has a market capitalization of $401.27 billion, a P/E ratio of 32.30, a price-to-earnings-growth ratio of 2.67 and a beta of 0.53. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company’s 50 day moving average price is $159.89 and its 200-day moving average price is $165.86.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is presently 99.58%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on JNJ shares. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Piper Sandler dropped their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.